Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PX'Therapeutics, which focuses on protein therapeutics, monoclonal antibodies and recombinant vaccines, is planning to open an additional cGMP production facility dedicated to mammalian cell culture, as part of its development strategy.
Subscribe to our email newsletter
The French regulatory authority (AFSSAPS) has authorized manufacturing operations including the production of biotechnology products, immunology products and extracted products from animal or human origin.
The new facility will allow cell banking as well as small scale production and release of protein batches intended for preclinical/clinical use and niche market (orphan disease, cell therapy).
The extension of the company’s production capabilities is expected to mark its ambition to support therapeutic antibody development.
PX’Therapeutics proposes custom programs targeting the development of monoclonal antibodies, humanization of therapeutic antibodies, protein engineering and optimization, feasibility studies, process development or small scale clinical manufacturing.